CYCLOTRONS AND POSITRON EMISSION TOMOGRAPHY RADIOPHARMACEUTICALS FOR CLINICAL IMAGING

被引:26
|
作者
SAHA, GB
MACINTYRE, WJ
GO, RT
机构
[1] Department of Nuclear Medicine, Cleveland Clinic Foundation, Cleveland, OH
关键词
D O I
10.1016/S0001-2998(05)80143-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Positron emission tomography (PET) requires positronemitting radionuclides that emit 511-keV photons detectable by PET imagers. Positron-emitting radionuclides are commonly produced in charged particle accelerators, eg, linear accelerators or cyclotrons. The most widely available radiopharmaceuticals for PET imaging are carbon-11-, nitrogen-13-, and oxygen-15-labeled compounds, many of which, either in their normal state or incorporated in other compounds, serve as physiological tracers. Other useful PET radiopharmaceuticals include fluorine-18-, bromine-75-, gallium-68 (68Ga)-, rubidium-82 (82Rb)-, and copper-62 (62Cu)-labeled compounds. Many positron emitters have short half-lives and thus require on-site cyclotrons for application, and others (68Ga, 82Rb, and 62Cu) are available from radionuclide generators using relatively long-lived parent radionuclides. This review is divided into two sections: cyclotrons and PET radiopharmaceuticals for clinical imaging. In the cyclotron section, the principle of operation of the cyclotron, types of cyclotrons, medical cyclotrons, and production of radionuclides are discussed. In the section on PET radiopharmaceuticals, the synthesis and clinical use of PET radiopharmaceuticals are described. © 1991 W.B. Saunders Company. All rights reserved.
引用
收藏
页码:150 / 161
页数:12
相关论文
共 50 条
  • [31] Positron emission tomography Imaging of clinical infectious diseases
    Van de Wiele, C
    De Winter, O
    Ham, H
    Dierckx, R
    MICROBIAL IMAGING, 2005, 34 : 199 - 212
  • [32] Positron emission tomography imaging (PET) in clinical practice
    González, P
    Massardo, T
    Canessa, J
    Humeres, P
    Jofré, J
    REVISTA MEDICA DE CHILE, 2002, 130 (05) : 569 - 579
  • [33] Analysis of radionuclide production in cyclotrons for application in positron emission tomography (PET)
    José Ródenas
    Eva Jabaloyas
    Journal of Radioanalytical and Nuclear Chemistry, 2019, 322 : 1691 - 1695
  • [34] Analysis of radionuclide production in cyclotrons for application in positron emission tomography (PET)
    Rodenas, Jose
    Jabaloyas, Eva
    JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, 2019, 322 (03) : 1691 - 1695
  • [35] Visualization with positron emission tomography, computed tomography, magnetic resonance imaging, positron emission tomography/computed tomography, and positron emission tomography/magnetic resonance imaging
    Seemann, MD
    Gaa, J
    CIRCULATION, 2005, 112 (21) : E329 - E330
  • [36] Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease
    Kjell Någren
    Christer Halldin
    Juha O. Rinne
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 1575 - 1593
  • [37] 68Ga-labeled radiopharmaceuticals for positron emission tomography
    Shetty D.
    Lee Y.-S.
    Jeong J.M.
    Nuclear Medicine and Molecular Imaging, 2010, 44 (4) : 233 - 240
  • [38] Pharmacopoeial Quality Standards for Radiopharmaceuticals for Positron-Emission Tomography
    Gromakov, A. S.
    Sakanyan, E. I.
    Senchenko, S. P.
    Ruziev, R. D.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2020, 54 (04) : 419 - 421
  • [39] Positron emission tomography: Evolving modalities, radiopharmaceuticals and professional collaboration
    Ayesa, Sally L.
    Murphy, Andrew
    JOURNAL OF MEDICAL RADIATION SCIENCES, 2022, 69 (04) : 415 - 418
  • [40] Radiopharmaceuticals in positron emission tomography: present situation and future perspectives
    Olivas Arroyo, C.
    RADIOLOGIA, 2016, 58 (06): : 468 - 480